LAKE FOREST, Ill. and LAKE BLUFF, Ill., Nov. 16 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Academic Pharmaceuticals, Inc (API), a research and development company specializing in cardiovascular products, announced today that Sotalol Hydrochloride (HCl) Injection for intravenous use is now available. Sotalol Hydrochloride tablets are currently available under the brand name Betapace(R).
Bioniche Pharma and API entered into an agreement whereby API developed and secured the FDA approval of Sotalol HCl Injection and Bioniche Pharma maintains the exclusive rights to manufacture, market, and distribute the product in the United States.
Sotalol HCl Injection is currently available and Bioniche Pharma will be attending the November
American Heart Association meeting in Orlando, Florida as part of their introduction of the product.
About Bioniche Pharma:
Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com.
Betapace(R) is a registered trademark of Bayer Schering Pharma.
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, email@example.comBioniche Pharma